SpinalCyte, a tissue engineering technology company focused on regrowth of the spinal disc nucleus using human dermal fibroblasts, has announced today the issuance of Australian Patent No. 2015202319, “Methods And Compositions For Repair of Cartilage Using An In Vivo Bioreactor.”
The technology described in the patent involves producing chondrocytes or chondrocyte-like cells using fibroblasts in vivo with mechanical stress and low oxygen tension.
“This Australian patent covers our core technology and provides the foundation for our intellectual property protection internationally. It solidifies our scientific basis and protects our technology in an extremely important market,” said Pete O’Heeron, Chief Executive Officer, SpinalCyte.
With this addition, SpinalCyte’s portfolio now includes 24 US and foreign patents issued and directly owned by the company, along with 45 patents pending. The company has previously received patents in the US, Canada, Japan, Europe and Australia.
In addition to its intellectual property portfolio, SpinalCyte has been working on an evidence base for its technology. In March 2016, results were announced from the company’s phase II human dermal fibroblast disc regeneration trial in rabbits. Final results were announced in April 2016. In January, the first patient was enrolled in a phase I human clinical trial of CybroCell, the first dermal fibroblast cell product for treatment of degenerative disc disease. The 18-patient trial received Institutional Review Board approval in 2016.